Deals news from FierceBiotech
News
BMS inks $227M collaboration deal with KAI
South San Francisco-based KAI Pharmaceuticals is getting a $25 million boost from Bristol-Myers Squibb---its upfront payment for a collaboration on KAI-9803, an experimental therapy to reduce the Read more...
Astellas pays $760M for Alzheimer's program
Another day, another big biotech deal. This time it's Japan's Astellas Pharma, which is paying $760 million for access to CoMentis's Alzheimer's drug. The development and commercialization agreement Read more...
SPOTLIGHT: Synta gains $80M from GSK
The FTC has cleared GlaxoSmithKline's deal with Synta, paving the way for Synta to receive an $80 million dollar up-front payment. Back in October GSK and Synta inked a $1.1 billion deal for Read more...
Axcan accepts $1.3 billion buyout offer
Canada's Axcan Pharma is being bought out for $1.3 billion by the private equity group TPG Capital. Shareholders will get a 28 percent premium over Wednesday's close while Axcan gains a new owner as Read more...
Indian developer inks R&D pact with Merck
China may have seized the spotlight in the Pacific Rim recently with a string of new research Read more...
Galapagos inks massive RA deal with J&J
Belgium-based Galapagos shares shot up 12 percent on news that the company has inked a massive deal with Jassen Pharmaceutica, a division of Johnson & Johnson. The deal, which is worth up to Read more...
SPOTLIGHT: Crucell, MedImmune strike deal
Dutch biotech Crucell has inked a joint venture deal with MedImmune to develop its bacterial antibodies to treat hospital-acquired infections. MedImmune has agreed to provide upfront, annual and Read more...
FDA, Gene Logic ink genomics deal
Gene Logic has inked an agreement with the FDA to share quality control methods and metrics that may Read more...
PTC Therapeutics gains $20M on new tech pact
These are good times for PTC Therapeutics, one of this year's Fierce 15. Just after being Read more...
Top 5 deals of the first half of 2007
Deal-making continued at a blistering pace in the first half of 2007, as drug giants snapped up promising therapies from smaller developers in order to beef up their pipelines. See the companies Read more...
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends